SABR-SCAN Trial for Pulmonary Oligometastases

Oligometastases Clinical Trial

— SABR-SCAN  

Official title:

Immediate Versus Delayed Stereotactic Ablative Radiotherapy (SABR) for Patients With Pulmonary Oligometastases From Colorectal Cancer: SABR SCAN Trial A Randomised Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02414334
• Other study ID #: RT2015-02
• Status: Completed
• Phase: N/A
• Start date: June 2015
• Est. completion date: June 2019

Study information

• Verified date: February 2024
• Source: University Medical Center Groningen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rationale:

SABR (Stereotactic ablative radiotherapy) is one of the standard treatment options besides surgical resection for limited lung metastases (oligometastases) from colorectal cancer. High efficacy in terms of local control of metastatic lesions treated has been shown. Nevertheless, the precise effect of SABR upon progression-free- and overall survival in these patients is unknown. To further evaluate and develop local treatment options in metastatic disease, more information is necessary regarding the impact upon - and the pattern of - disease progression of local treatment options such as SABR.

Objective:

To determine the effect upon progression free survival and upon tumorload relative to baseline, both at one year after randomisation of immediate SABR versus delayed SABR (a scan-and-personalise policy). Secondarily, patterns of progression, patient-reported symptoms and quality of life will be monitored.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 2019
• Est. primary completion date: June 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• WHO-Performance status (WHO-PS) 0 - 1

• Patients with 1 to 3 lung metastases between 8 mm and 3 cm each, from colorectal cancer. Resection has been considered at a multidisciplinary conference but was not recommended or has been refused by the patient.

• Possibility to define target lesions that fulfil the following criteria:

• No lesion larger than 3 cm;

• Not more than 3 metastases = 8 mm in total (lesions smaller than 8 mm in diameter are NOT counted and will NOT be irradiated);

• No prior radiotherapy (SABR or other) within about 2 cm from target lesions (i.e., the distance between prior planning-target-volume (PTV) to actual intended PTV is more than 2 cm AND dose distribution of former radiation permits SABR).

• Primary tumour has been completely removed surgically.

• Metastases outside target organs (e.g. liver metastases or other) are radically treated locally (resection, radiofrequency ablation (RFA), microwave ablation (MWA), stereotactic radiotherapy, or other). Earlier resected or ablated (SABR, RFA, MWA) metastases to lung, liver, or other organ form no exclusion criterion. Brain metastases should be completely resected or treated with stereotactic radiosurgery. Bone metastases should be resected or treated with high dose radiotherapy (equivalent of > 40 Gy) and be asymptomatic.

• Patients at reproductive potential must agree to practice an effective contraceptive method. Women of childbearing potential must not be pregnant or lactating.

• Proficiency in the Dutch language so that quality-of-life questionnaires can be completed in Dutch and absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.

• Before patient randomisation, informed consent must be given according to International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) of the European Union (EU) in accordance with good clinical practice (GCP), and national/local regulations.

Exclusion Criteria:

• Any clinical symptoms possibly or certainly caused by index lungmetastases

• Physical inability to undergo stereotactic radiotherapy (e.g., serious shoulder stiffness)

• Any uncontrolled malignancy other than index colorectal cancer

• Other malignancy within recent two years, even if completely under control (under control = no evidence of disease)

• Failure to comply with any of the inclusion criteria

Related Conditions & MeSH terms

• Oligometastases

Intervention

Radiation:
• Stereotactic Ablative Radiotherapy (SABR)

Locations

Country	Name	City	State
Netherlands	University Medical Center Groningen	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival (PFS)		12 months after randomisation
Secondary	Relative change of tumourload expressed as volume of all tumour at one year divided by volume of all tumour at time of randomisation;		12 months after randomisation
Secondary	Time to failure of local strategy (TFLS): failure = death or progressive disease NOT amenable to local treatment		when it occurs
Secondary	Progression of target lesions as measured by CT		12 months after randomisation
Secondary	Health-related quality of life profile	Euro-Qol 5 dimensions (EuroQoL-5D); Hospital Anxiety and Depression Scale (HADS); European Organization for Research and Treatment of Cancer quality of life questionnaire - lung cancer module (EORTC-QLQ-LC13)	Baseline; 3 months after randomisation and at 6, 9, 12, 15, 18, 21 and 24 months
Secondary	Progression of lesions other than target lesions as measured by CT		12 months after randomisation